MetrioPharm AG

MetrioPharm targets the modulation of immune metabolism with first-in-class self-regulating drug candidates. Our platform has generated small-molecule metabolic modulators that have demonstrated pre-clinical and clinical efficacy in a wide range of inflammatory and infective diseases with an outstanding safety profile. Further opportunities of our technology lie in metabolic modulation of the tumor micro-environment which holds promise for enhancing the efficacy of immune-oncological therapies.

Based on our core technology, we have created a diversified pipeline of disease-specific drug combinations to target inflammatory, autoimmune and degenerative diseases. Pre-clinical or clinical efficacy data have been obtained in Multiple Sclerosis, Arthritis, Sepsis, Inflammatory Bowel Disease and Psoriasis. The company is currently also exploring the orphan indication Duchenne Muscular Dystrophy.

In a second line of development, we are developing our technology to target infectious diseases like COVID-19. Supported by a EUR 7.5 million grant from the European Health Emergency Preparedness and Response Authority (HERA), a Phase II exploratory trial to evaluate the effect of MP1032 on hospitalized COVID-19 patients is currently ongoing (top line data in Q4 2022).